CRISPR Therapeutics AG
CRSPHealthcare|Biotechnology|Switzerland
$48.44
-0.71 (-1.44%)
Tangible Book
$20.04
Analyst Ratings
| Firm / Analyst | Rating | Price Target | Date |
|---|---|---|---|
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — | ||
| — | — |
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812"
],
"revenue_estimate": [
29.03,
76.4,
614.01
],
"ebit_estimate": [
-522.01,
-484.76,
-252.99
],
"ebitda_estimate": [
-463.68,
-440.58,
-326.97
],
"net_income_estimate": [
-474.72,
-427.85,
-254.77
],
"per_share_eps_estimate": [
-4.78,
-4.27,
-1.95
],
"eps_nri_estimate": [
-4.92,
-4.07,
-2.03
],
"dividend_estimate": [
null,
null,
null
],
"book_value_per_share_estimate": [
15.41,
11.69,
10.38
],
"pretax_income_estimate": [
-454.29,
-422.46,
-242.56
],
"operating_cash_flow_per_share_estimate": [
-3.1,
1,
4.41
],
"roa_estimate": [
-24.5,
-19.7,
5.2
],
"roe_estimate": [
-26.91,
-31.68,
-19.8
],
"gross_margin_estimate": [
91.65,
93.3,
92.73
],
"operating_cash_flow_estimate": [
-295.52,
95.01,
420.4
],
"pettm_estimate": [
0,
0,
0
],
"long_term_growth_rate_mean": 30.69,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 31.02,
"future_eps_nri_estimate_growth": 30.69,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 25.71,
"future_ebitda_estimate_growth": 18.86,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 22.74,
"future_pretax_income_estimate_growth": 23.49,
"future_book_value_per_share_estimate_growth": -20.15,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": 10.42,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202603",
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
1.89,
5.22,
7.37,
10.1,
13.65,
17.55,
28.08,
32.69
],
"ebit_estimate": [
-137.98,
-138.6,
-134.2,
-132.66,
-119.52,
-119.09,
-111.99,
-113.04
],
"ebitda_estimate": [
-113.52,
-106.86,
-105.11,
-101.31,
null,
null,
null,
null
],
"net_income_estimate": [
-118.87,
-117.06,
-112.63,
-111.95,
-100.27,
-100.41,
-93.76,
-95.37
],
"per_share_eps_estimate": [
-1.21,
-1.18,
-1.1,
-1.1,
-0.97,
-0.96,
-0.91,
-0.94
],
"eps_nri_estimate": [
-1.23,
-1.22,
-1.16,
-1.16,
-0.94,
-0.93,
-0.87,
-0.87
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
16.47,
15.41,
14.35,
13.3,
null,
null,
null,
null
],
"pretax_income_estimate": [
-122.92,
-122.84,
-120.09,
-120.03,
-99.67,
-99.71,
-93.06,
-94.57
],
"operating_cash_flow_per_share_estimate": [
-0.47,
-0.42,
-0.53,
-0.49,
null,
null,
null,
null
],
"roa_estimate": [
-3.8,
-4.1,
-5.2,
-5.1,
null,
null,
null,
null
],
"roe_estimate": [
-16.96,
-6.4,
-8.2,
-8.2,
null,
null,
null,
null
],
"gross_margin_estimate": [
80,
80,
80,
88.2,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
-44.8,
-40.04,
-50.52,
-46.23,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": 30.69,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 31.02,
"future_eps_nri_estimate_growth": 30.69,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 25.71,
"future_ebitda_estimate_growth": 18.86,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 22.74,
"future_pretax_income_estimate_growth": 23.49,
"future_book_value_per_share_estimate_growth": -20.15,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": 10.42,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}